PTC Therapeutics Inc. (NASDAQ:PTCT) shares saw unusually-high trading volume on Thursday . Approximately 1,582,644 shares were traded during trading, an increase of 58% from the previous session’s volume of 1,004,598 shares.The stock last traded at $7.55 and had previously closed at $7.11.

PTCT has been the topic of a number of recent analyst reports. Oppenheimer Holdings Inc. restated a “buy” rating and set a $39.00 price target on shares of PTC Therapeutics in a research note on Sunday, April 17th. Credit Suisse Group AG restated a “buy” rating on shares of PTC Therapeutics in a research note on Friday, May 6th. Jefferies Group restated a “hold” rating and set a $8.00 price target on shares of PTC Therapeutics in a research note on Friday, May 6th. Cowen and Company restated a “hold” rating on shares of PTC Therapeutics in a research note on Sunday, April 17th. Finally, Wedbush reiterated a “neutral” rating and issued a $11.00 price objective on shares of PTC Therapeutics in a research note on Wednesday, March 23rd. Two analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. PTC Therapeutics currently has a consensus rating of “Hold” and an average target price of $36.05.

The stock’s 50-day moving average is $7.37 and its 200-day moving average is $13.27. The company’s market cap is $254.73 million.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.04. The company had revenue of $18.90 million for the quarter, compared to analysts’ expectations of $13.74 million. The firm’s quarterly revenue was up 152.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.15) EPS. On average, analysts predict that PTC Therapeutics Inc. will post ($4.93) EPS for the current year.

Several hedge funds recently modified their holdings of the company. ProShare Advisors LLC increased its stake in shares of PTC Therapeutics by 10.6% in the fourth quarter. ProShare Advisors LLC now owns 32,490 shares of the biopharmaceutical company’s stock valued at $1,053,000 after buying an additional 3,122 shares in the last quarter. Rhumbline Advisers increased its stake in shares of PTC Therapeutics by 8.1% in the fourth quarter. Rhumbline Advisers now owns 33,247 shares of the biopharmaceutical company’s stock valued at $1,077,000 after buying an additional 2,485 shares in the last quarter. Marshall Wace LLP increased its stake in shares of PTC Therapeutics by 50.6% in the fourth quarter. Marshall Wace LLP now owns 44,410 shares of the biopharmaceutical company’s stock valued at $1,439,000 after buying an additional 14,926 shares in the last quarter. Turner Investments L.P. bought a new stake in shares of PTC Therapeutics during the fourth quarter valued at $1,532,000. Finally, Gratus Capital LLC increased its stake in shares of PTC Therapeutics by 9.7% in the fourth quarter. Gratus Capital LLC now owns 53,350 shares of the biopharmaceutical company’s stock valued at $1,729,000 after buying an additional 4,700 shares in the last quarter.

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.